{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:04:33Z","timestamp":1769043873009,"version":"3.49.0"},"reference-count":60,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2022,6,29]]},"abstract":"<jats:p>\n            Patients at risk of invasive fungal infections (IFIs), such as\n            <jats:named-content content-type=\"genus-species\">Aspergillus<\/jats:named-content>\n            spp., tend to be immunocompromised and usually take several medications which may generate many side effects. Prescribing is further complicated by comorbidities, drug interactions and challenges accessing diagnostics.\n          <\/jats:p>","DOI":"10.1128\/spectrum.00425-22","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T13:01:21Z","timestamp":1652101281000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United Kingdom"],"prefix":"10.1128","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2975-6509","authenticated-orcid":true,"given":"Stephanie R.","family":"Earnshaw","sequence":"first","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6216-8955","authenticated-orcid":true,"given":"Cheryl","family":"McDade","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Bryan","sequence":"additional","affiliation":[{"name":"Pfizer Biopharmaceuticals Group, Pfizer Ltd., Surrey, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Ines","sequence":"additional","affiliation":[{"name":"Hospital &amp; Vaccines Business Unit, Pfizer, Inc., Porto-Salvo, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christianne","family":"Micallef","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Sung","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Enoch","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1496"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2012.07.008"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-6515-1_2"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2016.10.005"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/597395"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8032"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.355"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/496927"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.042598"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.03.021"},{"key":"e_1_3_3_12_2","first-page":"275","article-title":"Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China","volume":"8","author":"Mao N","year":"2016","unstructured":"Mao N, Lesher B, Liu Q, Qin L, Chen Y, Gao X, Earnshaw SR, McDade CL, Charbonneau C. 2016. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China. Clinicoecon Outcomes Res 8:275\u2013285.","journal-title":"Clinicoecon Outcomes Res"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0443-1"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00850.x"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3683-2"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1638789"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2018-0119"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-013-1944-3"},{"key":"e_1_3_3_19_2","first-page":"705","article-title":"Is a biomarker-based diagnostic strategy for invasive aspergillosis cost effective in high-risk haematology patients?","volume":"55","author":"Macesic N","year":"2017","unstructured":"Macesic N, Morrissey CO, Liew D, Bohensky MA, Chen SC-A, Gilroy NM, Milliken ST, Szer J, Slavin MA. 2017. Is a biomarker-based diagnostic strategy for invasive aspergillosis cost effective in high-risk haematology patients? Med Mycol 55:705\u2013712.","journal-title":"Med Mycol"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01985-15"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1502659"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2263-6"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku506"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp507"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.06.012"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067975"},{"key":"e_1_3_3_28_2","unstructured":"Pfizer. 2021. Pfizer data on file. Antifungal use across treatment settings: latest Wave 3 market research \u2013 Conducted Nov 2019 - Feb 2020."},{"key":"e_1_3_3_29_2","unstructured":"CANCIDAS SmPC. 2020. CANCIDAS 50mg (formerly Caspofungin MSD) summary of product characteristics. Merck Sharp & Dohme Limited Hoddesdon Hertfordshire. http:\/\/www.medicines.org.uk\/emc\/medicine\/12843\/SPC\/."},{"key":"e_1_3_3_30_2","unstructured":"CRESEMBA SmPC. 2020. CRESEMBA (isavuconazole) summary of product characteristics. Pfizer Limited Sandwich Kent. https:\/\/www.medicines.org.uk\/emc\/product\/5069\/smpc."},{"key":"e_1_3_3_31_2","unstructured":"VFEND SmPC. 2020. VFEND (voriconazole) summary of product characteristics. Pfizer Limitedv Sandwich Kent. http:\/\/www.medicines.org.uk\/emc\/medicine\/10059\/SPC\/."},{"key":"e_1_3_3_32_2","unstructured":"AmBisome Liposomal SmPC. 2018. AmBisome Liposomal (liposomal amphotericin) summary of product characteristics. Gilead Sciences Ltd. Cambridge United Kingdom. https:\/\/www.medicines.org.uk\/emc\/product\/1022."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70076-8"},{"key":"e_1_3_3_35_2","volume-title":"Presented at the 51st Interscience Conference for Antimicrobial Agents and Chemotherapy","author":"Morrissey O","year":"2011","unstructured":"Morrissey O, Chen S, Slavin M. 2011. Randomized controlled trial of two diagnostic strategies for invasive aspergillosis (IA) in high-risk hematology patients. Presented at the 51st Interscience Conference for Antimicrobial Agents and Chemotherapy, Chicago, IL."},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043347"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401004"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200203000-00015"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040446"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01159-9"},{"key":"e_1_3_3_41_2","unstructured":"Fluconazole SmPC. 2020. Fluconazole summary of product characteristics. Milpharm Limited South Ruislip United Kingdom. https:\/\/www.medicines.org.uk\/emc\/product\/4722."},{"key":"e_1_3_3_42_2","unstructured":"Itraconazole SmPC. 2020. Itraconazole oral solution summary of product characteristics. Beacon Pharmaceuticals Tunbridge Wells Kent United Kingdom. https:\/\/www.medicines.org.uk\/emc\/product\/3293\/smpc."},{"key":"e_1_3_3_43_2","unstructured":"Posaconazole Sandoz SmPC. 2020. Posaconazole Sandoz (posaconazole) Summary of Product Characteristics. Sandoz Limited Camberley Surrey United Kingdom. https:\/\/www.medicines.org.uk\/emc\/product\/11190."},{"key":"e_1_3_3_44_2","unstructured":"National Health Service. 2016. Health Survey for England. 2016 trend tables. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/health-survey-for-england\/health-survey-for-england-2016."},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt508"},{"key":"e_1_3_3_46_2","unstructured":"GOV.UK. 2020. VAT rates. https:\/\/www.gov.uk\/vat-rates."},{"key":"e_1_3_3_47_2","volume-title":"Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Vienna, Austria","author":"Earnshaw S","year":"2021","unstructured":"Earnshaw S, McDade C, Bryan A, Ines M, Micallef C, Enoch D. 2021. Economic evaluation of diagnostic-driven versus empirical treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection. Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Vienna, Austria."},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-6-200109180-00010"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1159\/000100055"},{"key":"e_1_3_3_50_2","unstructured":"International Institute for Health Care and Excellence. 2020. British National Formulary. https:\/\/bnf.nice.org.uk\/."},{"key":"e_1_3_3_51_2","unstructured":"Fungizone SmPC. 2019. Fungizone (amphotericin) Summary of Product Characteristics. E.R. Squibb & Sons Limited Uxbridge. Middlesex United Kingdom. https:\/\/www.medicines.org.uk\/emc\/product\/10716."},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00071-2"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2016.1164175"},{"key":"e_1_3_3_54_2","unstructured":"National Health Service. 2020. National cost collection. National schedule of NHS costs year 2018-19. https:\/\/www.england.nhs.uk\/national-cost-collection\/#ncc1819."},{"key":"e_1_3_3_55_2","unstructured":"NICE. 2017. Fungitell for antifungal treatment stratification. Medtech innovation briefing. National Institute for Health and Care Excellence. https:\/\/www.nice.org.uk\/advice\/mib118\/resources\/fungitell-for-antifungal-treatment-stratification-pdf-2285963281484485."},{"key":"e_1_3_3_56_2","unstructured":"NICE. 2020. SepsiTest assay for rapidly identifying bloodstream bacteria and fungi diagnostics guidance [DG20]. National Institute for Health and Care Excellence. https:\/\/www.nice.org.uk\/guidance\/dg20\/chapter\/4-Outcomes#diagnostic-accuracy."},{"key":"e_1_3_3_57_2","volume-title":"Unit costs of health and social care.","author":"Curtis L","year":"2019","unstructured":"Curtis L, Burns A. 2019. Unit costs of health and social care. PSSRU, University of Kent, Kent, United Kingdom."},{"key":"e_1_3_3_58_2","unstructured":"Talent.com. 2021. Medical delivery driver average salary in United Kingdom. https:\/\/uk.talent.com\/salary?job=medical\u00b1delivery\u00b1driver."},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.02.014"},{"key":"e_1_3_3_60_2","unstructured":"Resuscitation Council (UK). 2015. Guidelines 2015. Adult tachycardia (with pulse) algorithm. https:\/\/www.resus.org.uk\/sites\/default\/files\/2020-05\/G2015_Adult_tachycardia.pdf."},{"key":"e_1_3_3_61_2","unstructured":"NICE. 2019. Hypertension in adults: diagnosis and management. NICE Guideline NG136. https:\/\/www.nice.org.uk\/guidance\/NG13."}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.00425-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.00425-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T14:01:08Z","timestamp":1656511268000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.00425-22"}},"subtitle":[],"editor":[{"given":"Renato","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6,29]]}},"alternative-id":["10.1128\/spectrum.00425-22"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.00425-22","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"2022-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00425-22"}}